Tag: jurisdictions

Toronto, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- In a significant step toward mainstreaming crypto-based passive income, Coinchange and Kanga Exchange have joined forces to offer automated yield solutions—resulting in over 30% user adoption in just months. The partnership between Coinchange, a digital asset management platform, and Kanga Exchange, a leading cryptocurrency exchange platform, demonstrates how the integration of yield-generating solutions can simplify access to passive income opportunities. The collaboration has enabled over 30% of Kanga’s active users to generate passive income through multi-strategy active portfolio management solutions on their digital asset holdings without requiring active supervision or technical expertise.

Manila, 12 June (Globe Newswire) –  iGaming.com officially announced the publication of its updated rankings to licensed online casinos in the Philippines for 2025, providing Filipino players with new insights into regulated operators, secure platforms, and responsible gaming resources. This newly released report reflects the latest market developments and regulatory updates affecting the Philippine iGaming sector. 

Press release
Paris, 12 June 2025

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.